All In MedTech

Device Trial Radar · NCT07720765

Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)

A National, Monocentric, Prospective Cohort Study to Evaluate the Utility and Applicability of Optical Coherence Tomography in Neurological Clinical Practice

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,050

Planned (sponsor's estimate)

Start

Oct 9, 2023

Primary completion

Apr 1, 2030

Study completion Apr 1, 2031

Sponsor

Lead sponsor
IRCCS San RaffaeleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 22, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

OCt.IN.N is a national, monocentric, prospective, observational cohort study evaluating the utility and applicability of Optical Coherence Tomography (OCT) in the diagnostic workup and longitudinal monitoring of neurological diseases. 840 patients with Central Nervous System neurological diseases (Multiple Sclerosis, Alzheimer's disease, Parkinson's disease, migraine/headache) and 210 age-matched healthy controls will undergo OCT examination at baseline and at 6, 12, 18, and 24 months of follow-up at IRCCS San Raffaele Hospital, Milan, Italy. OCT is a non-invasive, rapid, and reproducible technique that automatically measures the thickness of individual retinal layers. Retinal layer thicknesses and their longitudinal changes will be correlated with established clinical scales, neuroimaging, and biological markers used in routine neurological practice.

Conditions

  • Multiple Sclerosis
  • Alzheimer Disease
  • Parkinson Disease
  • Migraine
  • Headache Disorders

Interventions

  • Optical Coherence Tomography (OCT) - Heidelberg SPECTRALIS HRA+OCTDevice

    Spectral-domain Optical Coherence Tomography (OCT) performed using the Heidelberg SPECTRALIS HRA+OCT device (Class IIa CE-marked medical device). The procedure is non-invasive: the patient sits in front of the device and is asked to fix a target (light or cross) through a lens. No drugs or contrast agents are administered. OCT automatically acquires images of the macular region (where GCL and IPL are most represented) and the optic nerve head region (where RNFL is most represented), providing automated measurements of the thickness of individual retinal layers. OCT is performed at baseline and at follow-up visits at 6, 12, 18, and/or 24 months. Ophthalmological evaluation may be performed at the investigators' discretion if OCT images, clinical symptoms, or medical history suggest concurrent ocular pathology. Patients with a known diagnosis of epilepsy or history of epileptic seizures will not undergo specific imaging modes using clearly visible light sources (MultiColor, FA, BAF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual rate of peripapillary RNFL thinning in patients with Multiple Sclerosis vs healthy controlsTime frame: Baseline, 6, 12, 18, and 24 months
  2. Annual rate of peripapillary RNFL thinning in patients with Alzheimer's Disease vs healthy controlsTime frame: Baseline, 6, 12, 18, and 24 months
  3. Annual rate of peripapillary RNFL thinning in patients with Parkinson's Disease vs healthy controlsTime frame: Baseline, 6, 12, 18, and 24 months

6 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IRCCS Ospedale San Raffaele - Neurology and Neurophysiology Unit

    Milan, Milano, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.